A Pilot Study for PSMA Radioguided Detection and Removal of Metastatic Lymph Nodes in De Novo Metastatic Prostate Cancer Patients

--by Shilpi Aggarwal, PhD, Freelance Writer

Prostate cancer is one of the leading malignancies for mortality in men worldwide. Over the past decade, the identification of new biomarkers has led to an evolutionary shift in the detection, diagnosis, and treatment of metastatic prostate cancer. Prostate-specific membrane antigen (PSMA) is an important biomarker found to be abundant in >80% of prostate cancer patients.1 In metastatic prostate cancer a PSMA PET scan can be used to assess the progression of the disease and where it has spread in the body. In a study reported March 6, 2024 in The Journal of Nuclear Medicine, radioguided surgery targeting the PSMA was used to detect and remove metastatic pelvic lymph nodes in patients with de novo metastatic prostate cancer. The open-access article was the “featured article” of the month (March 2024) in the journal and is titled “Prostate-Specific Membrane Antigen–Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial.”

Login Or Register To Read Full Story